Advanced glycation end products formation pathway (AGE pathway) (AGE pathway)

The Advanced Glycation End products (AGE) formation pathway is a non-enzymatic process involving the reaction of reducing sugars with proteins, lipids, or nucleic acids, leading to irreversible cross-linking and structural damage (StatPearls, 2023). This pathway, often initiated by the Maillard reaction, results in the accumulation of AGEs which are implicated in the pathogenesis of aging and chronic diseases such as diabetes and Alzheimer's (PubMed, PMC6682902). AGEs exert their deleterious effects by altering the physical properties of the extracellular matrix and by binding to the Receptor for Advanced Glycation End products (RAGE), which activates pro-inflammatory and pro-oxidative signaling cascades (Nature Reviews Drug Discovery, 2004). Pharmacological intervention focuses on preventing AGE formation using dicarbonyl scavengers like pyridoxamine, breaking existing cross-links with agents like alagebrium, or inhibiting RAGE signaling with small molecules like azeliragon (Journal of Clinical Investigation, 2013). While targeting this pathway offers a broad therapeutic potential for diabetic complications and cardiovascular disease, clinical success has been limited by safety issues and the complexity of the glycation process in vivo (Diabetes Care, 2016). Overall, the AGE pathway represents a critical link between metabolic dysfunction and chronic tissue damage.

Other names

Maillard reactionNon-enzymatic glycation pathwayAGE-RAGE signaling pathwayGlycation pathway

Inhibition of non-enzymatic glycation, scavenging of reactive dicarbonyl precursors (e.g., methylglyoxal), breaking of established AGE cross-links, or antagonism of the Receptor for Advanced Glycation End products (RAGE).